To amend the Public Health Service Act to nullify certain contractual provisions prohibiting or penalizing a pharmacist's disclosure of the availability of therapeutically equivalent alternative drugs, or alternative methods of purchasing the prescription drug, that are less expensive, and for other purposes.
Health Subcommittee, Energy and Commerce Committee
Introduced
In Committee
On Floor
Passed Chamber
Enacted
Prescription Transparency Act of 2018 This bill prohibits contract provisions between a health insurer and a pharmacy that prohibit or penalize a pharmacist's disclosure to an individual purchasing a prescription drug of information regarding (1) the cost of the drug, (2) the availability of any therapeutically equivalent alternative drug, or (3) less expensive methods of purchasing the drug.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Health
Business ethicsConsumer affairsContracts and agencyDrug therapyHealth care costs and insuranceHealth personnelMedical ethicsPrescription drugs
To amend the Public Health Service Act to nullify certain contractual provisions prohibiting or penalizing a pharmacist's disclosure of the availability of therapeutically equivalent alternative drugs, or alternative methods of purchasing the prescription drug, that are less expensive, and for other purposes.
USA115th CongressHR-5343| House
| Updated: 3/23/2018
Prescription Transparency Act of 2018 This bill prohibits contract provisions between a health insurer and a pharmacy that prohibit or penalize a pharmacist's disclosure to an individual purchasing a prescription drug of information regarding (1) the cost of the drug, (2) the availability of any therapeutically equivalent alternative drug, or (3) less expensive methods of purchasing the drug.